Piperazine- and piperidine-derivatives as melanocortin receptor agonists
AssigneeEli Lilly and Company
InventorsKarin Briner, Christopher William Doecke, Vincent Mancuso, Michael John Martinelli, Timothy Ivo Richardson, Roger Ryan Rothhaar, Qing Shi, Chaoyu Xie
Life of this patent
Estimating the term…
Abstract
The present invention relates to melanocortin receptor agonists of formula I, which is useful in the treatment of obesity, diabetes and male and/or female sexual dysfunction. 1
Claims53
A compound of formula I:
- 320
- or a pharmaceutically acceptable salts or stereoisomers thereof, wherein
- G is CR1 or N;
- A is C1-C8 alkyl or C3-C7 cycloalkyl;
- L and L1 are independently:
- hydrogen or together oxo;
- T is:
- 321
- R is:
- when y is 1;
- N(R8)2, NR8COR8, NR8CON(R8)2, NR8C(O)OR8, NR8C(R8)═N(R8), NR8SO2R8 or NR8SO2N(R8)2;
- R is:
- when y is 0or 1;
- heterocyclyl, provided that when y is 0, a heteroatom is not directly connected to oxygen or adjacent to a carbon that connected to oxygen;
- and
- wherein the heterocyclyl contains at least one nitrogen in the ring and is optionally substituted with one to five substituents independently selected from R8;
- R1 is independently:
- hydrogen, CONH(C1-C8 alkyl), C1-C8 alkyl, (D)phenyl, (D)C3-C7 cycloalkyl or oxo, provided that oxo is not attached to the same carbon that attached to nitrogen which forms an amide bond when G is N;
- R2 is independently:
- hydrogen,
- halo
- C1-C8 alkyl,
- C1-C8 alkylsulfonyl,
- (D)C3-C7 cycloalkyl or
- C1-C4 haloalkyl;
- R3 is independently:
- aryl or thienyl;
- wherein aryl and thienyl are optionally substituted with one to three substituents selected from the group consisting of:
- cyano, halo, C1-C8 alkyl, (D)C3-C7 cycloalkyl, C1-C4 alkoxy, C1-C4 haloalkyl and C1-C4 haloalkyloxy;
- R4 is independently:
- hydrogen, C1-C8 alkyl, C(O)R8, C(O)OR8, C3-C7 cycloalkyl or (CH2)nO(C1-C8 alkyl), wherein n is 2-8;
- each R8 is independently:
- hydrogen,
- phenyl
- C1-C8 alkyl,
- C1-C8 alkylsulfonyl,
- C(O)C1-C8 alkyl,
- C(O)aryl, wherein aryl being phenyl or naphthyl,
- SO2-aryl, wherein aryl being phenyl or naphthyl,
- (D)C3-C7 cycloalkyl or
- (CH2)nC1-C4 haloalkyl, wherein n is 1-8;
- each R9 is independently:
- hydrogen,
- hydroxy,
- (D)cyano,
- halo,
- C1-C8 alkyl,
- C1-C8 alkoxy,
- C3-C7 cycloalkyl,
- C1-C4 haloalkyl,
- (D)heterocyclyl
- (D)C(O)R8,
- (D)C(O)(CH2)nN(R8)2,
- C1-C8 alkyl-N(R8)2,
- (D)OR8,
- (D)OCOR8,
- (D)OC(O)N(R8)2,
- (D)N(R8 )2,
- (D)NR8C(O)R8,
- (D)NR8C(O)OR8,
- (D)NR8C(O)N(R8)2,
- (D)NR8SO2R8,
- (D)SR8,
- (D))SOR8,
- (D)SO2R8, or
- (D)SO2N(R8)2;
- each R10 is independently:
- hydrogen, (C1-C8)alkyl, C(O)C1-C8 alkyl, aryl or C3-C7 cycloalkyl;
- each R11 is independently:
- hydrogen,
- C1-C8 alkyl,
- (D)aryl,
- (D)heteroaryl
- (CH2)nN(R8)2,
- (CH2)nNR8C(O)C1-C4 alkyl,
- (CH2)nNR8SO2C1-C4 alkyl,
- (CH2)nSO2N(R8)2,
- (CH2)n[O]qC1-C8 alkyl,
- (CH2)n[O]q(CH2)nNR8COR8,
- (CH2)n[O]q(CH2)nNR8SO2R8,
- (CH2)n[O]qheterocyclyl or
- (CH2)n[O]q(C1-C8 alkyl)-heterocyclyl;
- and
- wherein n is 2-8;
- each R12 is independently:
- hydrogen,
- C1-C8 alkyl,
- (D))C3-C7 cycloalkyl,
- (D)phenyl
- C(O)C1-C8 alkyl,
- C(O)phenyl,
- SO2C1-C8 alkyl or
- SO2-phenyl;
- D is a bond or —(CH2)n—;
- n is 0-8;
- p is 0-4;
- q is 0-1;
- r is 1-2;
- and
- y is 0-1.
A compound of formula II,
- 323
- or a pharmaceutically acceptable salts or stereoisomers thereof, wherein
- A is C1-C8 alkyl or C3-C7 cycloalkyl;
- r is O or 1;
- y is O or 1;
- D is a bond or —(CH2)n—;
- n is 0-8;
- R is:
- when y is 1;
- N(R8)2, NR8COR8, NR8CON(R8)2, NR8C(O)OR8, NR8C(R8)═N(R8), NR8SO2R8 or NR8SO2N(R8)2;
- R is:
- when y is 0 or 1;
- heterocyclyl, provided that when y is 0, a heteroatom is not directly connected to oxygen or adjacent to a carbon that connected to oxygen;
- and
- wherein the heterocyclyl contains at least one nitrogen in the ring and is optionally substituted with one to five substituents independently selected from R8;
- each R8 is independently:
- hydrogen,
- phenyl
- C1-C8 alkyl,
- C1-C8 alkylsulfonyl,
- C(O)C1-C8 alkyl,
- C(O)aryl, wherein aryl being phenyl or naphthyl,
- SO2-aryl, wherein aryl being phenyl or naphthyl,
- (D)C3-C7 cycloalkyl or
- (CH2)nC1-C4 haloalkyl, wherein n is 1-8;
- each R10 is independently:
- hydrogen, (C1-C8)alkyl, C(O)C1-C8 alkyl, aryl or C3-C7 cycloalkyl.
A compound of formula III,
- 324
- or a pharmaceutically acceptable salts or stereoisomers thereof, wherein
- A is C1-C8 alkyl or C3-C7 cycloalkyl;
- y is 0or 1;
- D is a bond or —(CH2)n—;
- n is 0-8;
- R is:
- when y is 1;
- N(R8)2, NR8COR8, NR8CON(R8)2, NR8C(O)OR8, NR8C(R8)═N(R8), NR8SO2R8 or NR8SO2N(R8)2;
- R is:
- when y is 0or 1;
- heterocyclyl, provided that when y is 0, a heteroatom is not directly connected to oxygen or adjacent to a carbon that connected to oxygen;
- and
- wherein the heterocyclyl contains at least one nitrogen in the ring and is optionally substituted with one to five substituents independently selected from R8;
- and
- each R8 is independently:
- hydrogen,
- phenyl
- C1-C8 alkyl,
- C1-C8 alkylsulfonyl,
- C(O)C1-C8 alkyl,
- C(O)aryl, wherein aryl being phenyl or naphthyl,
- SO2-aryl, wherein aryl being phenyl or naphthyl,
- (D)C3-C7 cycloalkyl or
- (CH2)nC1-C4 haloalkyl, wherein n is 1-8;
A compound of formula IV,
- 325
- or a pharmaceutically acceptable salts or stereoisomers thereof, wherein
- A is C1-C8 alkyl or C3-C7 cycloalkyl;
- r is 0 or 1;
- y is 0 or 1;
- D is a bond or —(CH2)n—;
- n is 0-8;
- R is:
- when y is 1;
- N(R8)2, NR8COR8, NR8CON(R8)2, NR8C(O)OR8, NR8C(R8)═NR8), NR8SO2R8 or NR8SO2N(R8)2;
- R is:
- when y is 0or 1;
- heterocyclyl, provided that when y is 0, a heteroatom is not directly connected to oxygen or adjacent to a carbon that connected to oxygen;
- and
- wherein the heterocyclyl contains at least one nitrogen in the ring and is optionally substituted with one to five substituents independently selected from R8;
- each R8 is independently:
- hydrogen,
- phenyl
- C1-C8 alkyl,
- C1-C8 alkylsulfonyl,
- C(O)C1-C8 alkyl,
- C(O)aryl, wherein aryl being phenyl or naphthyl,
- SO2-aryl, wherein aryl being phenyl or naphthyl,
- (D)C3-C7 cycloalkyl or
- (CH2)nC1-C4 haloalkyl, wherein n is 1-8;
- each R10 is independently:
- hydrogen, (C1-C8)alkyl, C(O)C1-C8 alkyl, aryl or C3-C7 cycloalkyl.
A compound of formula V,
- 326
- or a pharmaceutically acceptable salts or stereoisomers thereof, wherein
- A is C1-C8 alkyl or C3-C7 cycloalkyl;
- y is 0 or 1;
- D is a bond or —(CH2)n—;
- n is 0-8;
- R is:
- when y is 1;
- N(R8)2, NR8COR8, NR8CON(R8)2, NR8C(O)OR8, NR8C(R8)═N(R8), NR8SO2R8 or NR8SO2N(R8)2;
- R is:
- when y is 0 or 1;
- heterocyclyl, provided that when y is 0, a heteroatom is not directly connected to oxygen or adjacent to a carbon that connected to oxygen;
- and
- wherein the heterocyclyl contains at least one nitrogen in the ring and is optionally substituted with one to five substituents independently selected from R8;
- each R8 is independently:
- hydrogen,
- phenyl
- C1-C8 alkyl,
- C1-C8 alkylsulfonyl,
- C(O)C1-C8 alkyl,
- C(O)aryl, wherein aryl being phenyl or naphthyl,
- SO2-aryl, wherein aryl being phenyl or naphthyl,
- (D)C3-C7 cycloalkyl or
- (CH2)nCl -C4 haloalkyl, wherein n is 1-8;
A compound of formula VI,
- 327
- or a pharmaceutically acceptable salts or stereoisomers thereof, wherein
- A is C1-C8 alkyl or C3-C7 cycloalkyl;
- y is 0 or 1;
- D is a bond or —(CH2)n—;
- n is 0-8;
- R is:
- when y is 1;
- N(R8)2, NR8COR8, NR8CON(R8)2, NR8C(O)OR8, NR8C(R8)═N(R8), NR8SO2R8 or NR8SO2N(R8)2;
- R is:
- when y is 0or 1;
- heterocyclyl, provided that when y is 0, a heteroatom is not directly connected to oxygen or adjacent to a carbon that connected to oxygen;
- and
- wherein the heterocyclyl contains at least one nitrogen in the ring and is optionally substituted with one to five substituents independently selected from R8;
- each R8 is independently:
- hydrogen,
- phenyl
- C1-C8 alkyl,
- C1-C8 alkylsulfonyl,
- C(O)C1-C8 alkyl,
- C(O)aryl, wherein aryl being phenyl or naphthyl,
- SO2-aryl, wherein aryl being phenyl or naphthyl,
- (D)C3-C7 cycloalkyl or
- (CH2)nC1-C4 haloalkyl, wherein n is 1-8;
A compound selected from the group consisting of:
- 16 Name of Compound Compound (N-(1-(4-R-chlorobenzyl)-2-{4-[2- (1-methyl-S-piperidin-3-yloxy)- phenyl]-piperazin-1-yl}-2-oxo- ethyl)-2-(2,3-dihydro-1H-isoindol-1- yl)-aceamide, trihydrochloride 328 (N-(1-(4-R-chlorobenzyl)-2-oxo-2- {4-[2-(R-piperidin-3-yloxy)- phenyl]-piperazin-1-yl}ethyl)-2- (2,3-dihydro-1H-isoindol-1-yl)- aceamide, trihydrochloride 329 2-(2,3-dihydro-1H-isoindol-1-yl)-N- (1-(4-methoxy-benzyl)-2-{4-[2-(1- methyl-piperidin-3-yloxy)-phenyl]- piperazin-1-yl)-2-oxo-ethyl)- acetaimde, trihydrochloride 330
The method of 40, wherein the male or female sexual dysfunction is erectile dysfunction.
A process for preparing a compound of formula I:
- 331
- or a pharmaceutically acceptable salts or stereoisomers thereof, wherein
- G is CR1 or N;
- A is C1-C8 alkyl or C3-C7 cycloalkyl;
- —CLL1-(CH2)n-T is:
- 332
- wherein R1 is hydrogen, C1-C8 alkyl, Boc, CBZ, FMOC, phenyl or (C1-C8 alkyl)phenyl;
- Q represents a moiety:
- 333
- R is:
- when y is 1;
- N(R8)2, NR8COR8, NR8CON(R8)2, NR8C(O)OR8, NR8C(R8)═N(R8), NR8SO2R8 or NR8SO2N(R8)2;
- R is:
- when y is 0 or 1;
- heterocyclyl provided that when y is 0, a heteroatom is not directly connected to oxygen or adjacent to a carbon that connected to oxygen;
- and
- wherein the heterocyclyl contains at least one nitrogen in the ring and is optionally substituted with one to five substituents independently selected from R8;
- R1 is independently:
- hydrogen, CONH(C1-C8 alkyl), C1-C8 alkyl, (D)phenyl, (D)C3-C7 cycloalkyl or oxo, provided that oxo is not attached to the same carbon that attached to nitrogen which forms an amide bond when G is N;
- R2 is independently:
- hydrogen,
- halo
- C1-C8 alkyl,
- C1-C8 alkylsulfonyl,
- (D)C3-C7 cycloalkyl or
- C1-C4 haloalkyl;
- R3 is independently:
- aryl or thienyl;
- wherein aryl and thienyl are optionally substituted with one to three substituents selected from the group consisting of:
- cyano, halo, C1-C8 alkyl, (D)C3-C7 cycloalkyl, C1-C4 alkoxy, C1-C4 haloalkyl and C1-C4 haloalkyloxy;
- R4 is independently:
- hydrogen, C1-C8 alkyl, C(O)R8, C(O)OR8, C3-C7 cycloalkyl or (CH2)nO(C1-C8 alkyl), wherein n is 2-8;
- each R8 is independently:
- hydrogen,
- phenyl
- C1-C8 alkyl,
- C1-C8 alkylsulfonyl,
- C(O)C1-C8 alkyl,
- C(O)aryl, wherein aryl being phenyl or naphthyl,
- SO2-aryl, wherein aryl being phenyl or naphthyl,
- (D)C3-C7 cycloalkyl or
- (CH2)nC1-C4 haloalkyl, wherein n is 1-8;
- each R9 is independently:
- hydrogen,
- hydroxy,
- (D)cyano,
- halo,
- C1-C8 alkyl,
- C1-C8 alkoxy,
- C3-C7 cycloalkyl,
- C1-C4 haloalkyl,
- (D)heterocyclyl
- (D)C(O)R8,
- (D)C(O)(CH2)nN(R8)2,
- C1-C8 alkyl-N(R8)2,
- (D)OR8,
- (D)OCOR8,
- (D)OC(O)N(R8)2,
- (D)N(R8)2,
- (D)NR8C(O)R8,
- (D)N8C(O)OR8,
- (D)NR8C(O)N(R8)2,
- (D)NR8SO2R8,
- (D)SR8,
- (D)SOR8,
- (D)SO2R8, or
- (D)SO2N(R8)2;
- each R10 is independently:
- hydrogen, (C1-C8)alkyl, C(O)C1-C8 alkyl, aryl or C3-C7 cycloalkyl;
- D is a bond or —(CH2)n—;
- n is 0-8;
- p is 0-4;
- q is 0-1;
- r is 1-2;
- and
- y is 0-1;
- comprising the steps of:
- a) reacting a compound having a structural formula 1,
- 334
- with CH2CH═C(O)ORa wherein Ra is hydrogen or C1-C8 alkyl and X is halo, in the presence of a catalyst and a base in a suitable organic solvent to give the compound of formula 2,
- 335
- b) reductively aminating the compound of formula 2 in the presence of amine in an acidic condition to give a compound of formula 3,
- 336
- c) cyclizing the compound of formula 3 by Michael addition to give a compound of formula 4 or stereoisomers thereof,
- 337
- d) coupling the compound of formula 4 or stereoisomers thereof, wherein Ra of compound 4 is H, with a compound of formula 5,
- 338
- wherein Ra of compound 5 is C1-C8 alkyl, to give a compound of formula 6;
- 339
- e) coupling the compound of formula 6, wherein Ra is H, with a compound having a structural,
- 340
- to afford the compound of formula 1.
A process for preparing a compound of formula I:
- 344
- or a pharmaceutically acceptable salts or stereoisomers thereof, wherein
- G is CR1 or N;
- A is C1-C8 alkyl or C3-C7 cycloalkyl;
- -CLL1-(CH2)n-T is:
- 345
- Q represents a moiety:
- 346
- R is:
- when y is 1;
- N(R8)2, NR8COR8, NR8CON(R8)2, NR8C(O)OR8, NR8C(R8)═N(R8), NR8SO2R8 or NR8SO2N(R8)2;
- R is:
- when y is 0 or 1;
- heterocyclyl, provided that when y is 0, a heteroatom is not directly connected to oxygen or adjacent to a carbon that connected to oxygen;
- and
- wherein the heterocyclyl contains at least one nitrogen in the ring and is optionally substituted with one to five substituents independently selected from R8;
- R1 is independently:
- hydrogen, CONH(C1-C8 alkyl), C1-C8 alkyl, (D)phenyl, (D)C3-C7 cycloalkyl or oxo, provided that oxo is not attached to the same carbon that attached to nitrogen which forms an amide bond when G is N;
- R2 is independently:
- hydrogen,
- halo
- C1-C8 alkyl,
- C1-C8 alkylsulfonyl,
- (D)C3-C7 cycloalkyl or
- C1-C4 haloalkyl;
- R3 is independently:
- aryl or thienyl;
- wherein aryl and thienyl are optionally substituted with one to three substituents selected from the group consisting of:
- cyano, halo, C1-C8 alkyl, (D)C3-C7 cycloalkyl, C1-C4 alkoxy, C1-C4 haloalkyl and C1-C4 haloalkyloxy;
- R4 is independently:
- hydrogen, C1-C8 alkyl, C(O)R8, C(O)OR8, C3-C7 cycloalkyl or (CH2)nO(C1-C8 alkyl), wherein n is 2-8;
- each R8 is independently:
- hydrogen,
- phenyl
- C1-C8 alkyl,
- C1-C8 alkylsulfonyl,
- C(O)C1-C8 alkyl,
- C(O)aryl, wherein aryl being phenyl or naphthyl,
- SO2-aryl, wherein aryl being phenyl or naphthyl,
- (D)C3-C7 cycloalkyl or
- (CH2)nC1-C4 haloalkyl, wherein n is 1-8;
- each R9 is independently:
- hydrogen,
- hydroxy,
- (D)cyano,
- halo,
- C1-C8 alkyl,
- C1-C8 alkoxy,
- C3-C7 cycloalkyl,
- C1-C4 haloalkyl,
- (D)heterocyclyl
- (D)C(O)R8,
- (D)C(O)(CH2)nN(R8)2,
- C1-C8 alkyl-N(R8)2,
- (D)OR8,
- (D)OCOR8,
- (D)OC(O)N(R8)2,
- (D)N(R8 )2,
- (D)NR8C(O)R8,
- (D)NR8C(O)OR8,
- (D)NR8C(O)N(R8)2,
- (D)NR8SO2R8,
- (D)SR8,
- (D)SOR8,
- (D)SO2R8, or
- (D)SO2N(R8)2;
- each R11 is independently:
- hydrogen or (C1-C8)alkyl;
- D is a bond or —(CH2)n—;
- n is 0-8;
- p is 0-4;
- q is 0-1;
- r is 1-2;
- and
- y is 0-1;
- comprising the steps of:
- a) esterifying a compound of formula 1,
- 347
- with an alcohol RaOH to form a compound of formula 2,
- 348
- wherein Ra is C1-C4 alkyl or (D)phenyl;
- b) reacting a compound of formula 2 with R11COR11 to form a compound of formula 3,
- 349
- wherein R11 is independently hydrogen or C1-C4 alkyl;
- c) reacting a compound of formula 3 with an activating group to form a compound of formula 4,
- 350
- wherein A is an activating group;
- d) deoxygenating the compound of formula 4 by hydrogenation to afford a compound of formula 5,
- 351
- e) optionally reacting the compound of formula 5 with an inorganic base to form a compound of formula 6,
- 352
- wherein HA is an acidic and M is a univalent cation;
- f) resolving the compound of formula 5 or formula 6 to afford a chiral compound of formula 7,
- 353
- wherein M is hydrogen and Ra′ is H or Ra;
- g) coupling the compound of formula 7 with a compound of formula 8,
- 354
- to afford a compound of formula 9,
- 355
- h) coupling the compound of formula 9 with a compound having a formula,
- 356
- to afford a compound of formula I.
A process for preparing a compound of formula I:
- 357
- or a pharmaceutically acceptable salts or stereoisomers thereof, wherein
- G is CR1 or N;
- A is C1-C8 alkyl or C3-C7 cycloalkyl;
- -CLL1-(CH2)n-T is:
- 358
- Q represents a moiety:
- 359
- R is:
- when y is 1;
- N(R8)2, NR8COR8, NR8CON(R8)2, NR8C(O)OR8, NR8C(R8)═N(R8), NR8SO2R8 or NR8SO2N(R8)2;
- R is:
- when y is 0or 1;
- Heterocyclyl, provided that when y is 0, a heteroatom is not directly connected to oxygen or adjacent to a carbon that connected to oxygen;
- and
- wherein the heterocyclyl contains at least one nitrogen in the ring and is optionally substituted with one to five substituents independently selected from R8;
- R1 is independently:
- hydrogen, CONH(C1-C8 alkyl), C1-C8 alkyl, (D)phenyl, (D)C3-C7 cycloalkyl or oxo, provided that oxo is not attached to the same carbon that attached to nitrogen which forms an amide bond when G is N;
- R2 is independently:
- hydrogen,
- halo
- C1-C8 alkyl,
- C1-C8 alkylsulfonyl,
- (D)C3-C7 cycloalkyl or
- C1-C4 haloalkyl;
- R3 is independently:
- aryl or thienyl;
- wherein aryl and thienyl are optionally substituted with one to three substituents selected from the group consisting of:
- cyano, halo, C1-C8 alkyl, (D)C3-C7 cycloalkyl, C1-C4 alkoxy, C1-C4 haloalkyl and C1-C4 haloalkyloxy;
- R4 is independently:
- hydrogen, C1-C8 alkyl, C(O)R8, C(O)OR8, C3-C7 cycloalkyl or (CH2)nO(C1-C8 alkyl), wherein n is 2-8;
- each R8 is independently:
- hydrogen,
- phenyl
- C1-C8 alkyl,
- C1-C8 alkylsulfonyl,
- C(O)C1-C8 alkyl,
- C(O)aryl, wherein aryl being phenyl or naphthyl,
- SO2-aryl, wherein aryl being phenyl or naphthyl,
- SO2C1-C8 alkyl,
- (D)C3-C7 cycloalkyl or
- (CH2)nC1-C4 haloalkyl, wherein n is 1-8;
- each R9 is independently:
- hydrogen,
- hydroxy,
- (D)cyano,
- halo,
- C1-C8 alkyl,
- C1-C8 alkoxy,
- C3-C7 cycloalkyl,
- C1-C4 haloalkyl,
- (D)heterocyclyl
- (D)C(O)R8,
- (D)C(O)(CH2)nN(R8)2,
- C1-C8 alkyl-N(R8)2,
- (D)OR8,
- (D)OCOR8,
- (D)OC(O)N(R8)2,
- (D)N(R8)2,
- (D)NR8C(O)R8,
- (D)NR8C(O)OR8,
- (D)NR8C(O)N(R8)2,
- (D))NR8SO2R8,
- (D)SR8,
- (D)SOR8,
- (D)SO2R8, or
- (D)SO2N(R8)2;
- each R10 is independently:
- hydrogen, (C1-C8)alkyl, C(O)C1-C8 alkyl, aryl C3-C7 cycloalkyl, or protecting group selected from Boc, CBZ or FMOC;
- each R1 1 is independently:
- hydrogen or (C1-C8)alkyl;
- D is a bond or —(CH2)n—;
- n is 0-8;
- p is 0-4;
- q is 0-1;
- r is 1-2;
- and
- y is 0-1;
- comprising the steps of:
- a) reacting a compound formula 1:
- 360
- wherein X is halo, and R11 is independently, hydrogen or C1-C4 alkyl, with CNCH2CO2Ra wherein Ra is C1-C8 alkyl or benzyl to afford a compound of formula 2:
- 361
- b) protecting the compound of formula 2 to form the compound of formula 3:
- 362
- c) hydrogenating the compound of formula 3 to afford a compound of formula 4:
- 363
- d) coupling the compound of formula 4 wherein Ra′ is hydrogen or Ra, with a compound of formula 5,
- 364
- to afford a compound of formula 6,
- 365
- e) coupling the compound of formula 6 with a compound having a formula,
- 366
- to afford a compound of formula I.
Dependencies are inferred from the claim text.